MLSS vs. INGN, TLSI, PROF, CVRX, ELMD, KRMD, PDEX, LNSR, RCEL, and AVR
Should you be buying Milestone Scientific stock or one of its competitors? The main competitors of Milestone Scientific include Inogen (INGN), TriSalus Life Sciences (TLSI), Profound Medical (PROF), CVRx (CVRX), Electromed (ELMD), KORU Medical Systems (KRMD), Pro-Dex (PDEX), LENSAR (LNSR), Avita Medical (RCEL), and Anteris Technologies Global (AVR). These companies are all part of the "medical equipment" industry.
Milestone Scientific vs. Its Competitors
Inogen (NASDAQ:INGN) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.
Inogen currently has a consensus price target of $11.00, indicating a potential upside of 58.96%. Milestone Scientific has a consensus price target of $1.25, indicating a potential upside of 87.58%. Given Milestone Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Milestone Scientific is more favorable than Inogen.
Inogen has a net margin of -8.08% compared to Milestone Scientific's net margin of -52.01%. Inogen's return on equity of -14.76% beat Milestone Scientific's return on equity.
In the previous week, Milestone Scientific had 3 more articles in the media than Inogen. MarketBeat recorded 7 mentions for Milestone Scientific and 4 mentions for Inogen. Inogen's average media sentiment score of 0.47 beat Milestone Scientific's score of 0.37 indicating that Inogen is being referred to more favorably in the media.
89.9% of Inogen shares are held by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are held by institutional investors. 1.5% of Inogen shares are held by insiders. Comparatively, 24.8% of Milestone Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Milestone Scientific has lower revenue, but higher earnings than Inogen. Milestone Scientific is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
Inogen has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Milestone Scientific has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
Summary
Inogen beats Milestone Scientific on 8 of the 15 factors compared between the two stocks.
Get Milestone Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Scientific Competitors List
Related Companies and Tools
This page (NYSE:MLSS) was last updated on 7/11/2025 by MarketBeat.com Staff
Free MLSS Stock Alerts